Navigation Links
UC San Diego's Karin receives prestigious Harvey Prize
Date:9/8/2010

Michael Karin, PhD, Distinguished Professor of Pharmacology and Pathology at the University of California, San Diego School of Medicine has been awarded the 2010 Harvey Prize in human health by the Technion, Israel's premier institute of technology.

The prize honors Karin's seminal research linking obesity, inflammation and cancer. Specifically, judges noted Karin's "pioneering contributions" to the deciphering of the molecular mechanism used by mammalian cells to react to cytokines (proteins that cause inflammation), to adverse environmental conditions and to various pathogens. "These discoveries," the judges said, have "led to the identification of new target proteins that have recently been used to develop new medications for preventing and treating various malignant tumors."

Karin will accept the Harvey Prize at a ceremony at the Technion in Haifa, Israel on March 15, 2011, along with Alexander Polyakov, a theoretical physicist at Princeton University who is receiving the 2010 Harvey Prize for science and technology, based upon his work in quantum field theory. Each recipient will receive a $75,000 cash award.

At UC San Diego, Karin and colleagues have long been interested in how cells and biological systems function at the molecular level in both healthy and stressed or diseased states. The research has broad, practical implications and applications, notably in issues like obesity and cancer.

"In addition to its well-known contribution to cardiovascular disease and metabolic disorders, such as type II diabetes, obesity has been found to increase cancer risk," said Karin. "Of all cancers, the one most affected by obesity is liver cancer, the third leading cause of cancer-related deaths worldwide. Our work has shown that obesity promotes the development of liver cancer through inflammatory mechanisms similar to those we elucidated earlier in colorectal cancer, another very common inflammation-promoted cancer."

Karin's lab has identified cytokines and responding transcription factors involved in these cancers. Drugs that inhibit activation of a key transcription factor called STAT3 are in development and slated for clinical trials soon.


'/>"/>

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert  

Related medicine news :

1. K-State receives patent for noncontroversial source of stem cells
2. St. Jude researcher receives grant to focus on cancer pharmacogenomics in children
3. Penn receives $12 million NIH grant to research personalized approach to smoking cessation
4. Health IT program at the University of Texas at Austin receives $2.7 million in federal funding
5. University of Minnesota math institute receives $20.5 million NSF grant
6. College Of Medicine receives $54 million grant for asthma research
7. Louisiana Tech kinesiology professor receives national editorial excellence award
8. UofL receives $3.15 million grant from Helmsley Charitable Trust
9. St. Michaels receives prestigious grants to study trauma
10. Doctor at Cincinnati Childrens receives prestigious NIH MERIT Award
11. Research consortium at CHLA receives $410,000 to study leukemia and lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UC San Diego's Karin receives prestigious Harvey Prize
(Date:3/29/2017)... ... ... Curio Wellness , a premium medical cannabis brand and trusted healthcare ... team with prominent executives from both inside and outside the cannabis industry. , ... Dumbauld , who has more than twenty years of business leadership and investment experience ...
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an important webinar — ... 1:00 PM ET. A recording of the webinar will also be made available following ... health and hospice companies are still popular targets for healthcare investors. This highly fragmented ...
(Date:3/29/2017)... ... 2017 , ... Immunotherapy has emerged as one of the most promising options ... be the next revolution in our fight against this complex disease. One of the ... checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single analyte ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... Hills of Pittsburgh now have easier access to the robotic-assisted total-hip and ... Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital recently ...
(Date:3/29/2017)... ... , ... The Wharton School of the University of Pennsylvania is pleased to ... $10 million gift to establish the Ken Moelis and Julie Taffet Moelis Advance ... Wharton MBA for highly-qualified Penn undergraduates whose academic and career interests expand traditional notions ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... March 29, 2017  Maxor National Pharmacy Services, LLC ... it has named Leah Bailey as General ... of the company. With more than 13 ... 8 years focused on health care, Bailey joins the ... at Prime, Bailey advised the PBM, Specialty, and Mail ...
(Date:3/29/2017)... WASHINGTON , March 29, 2017  The Pharmaceutical ... regarding a new PhRMA report on patient out-of-pocket spending: ... for Medicare and Medicaid Services (CMS), the average amount ... be 13% of drug spending in 2016, down from ... is a pricing problem, not a coverage problem. Health ...
(Date:3/29/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The ablation device global market is expected to grow ... Ablation is the minimally invasive therapeutic tissue excision ... diseased tissue removal, to the removal of abnormally conducting cardiac tissue ...
Breaking Medicine Technology: